Denka Company Limited (TYO:4061)

Marinus Pharmaceuticals Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	399,091	400,251	389,263	407,559	384,849	354,391
Revenue Growth (YoY)	0.61%	2.82%	-4.49%	5.90%	8.59%	-6.94%
Cost of Revenue	316,534	315,655	306,762	305,217	277,674	254,196
Gross Profit	82,557	84,596	82,501	102,342	107,175	100,195
Selling, General & Admin	70,559	57,734	56,409	57,333	55,114	52,985
Research & Development	-	12,445	12,680	12,680	11,947	12,501
Operating Expenses	70,559	70,182	69,124	70,017	67,051	65,464
Operating Income	11,998	14,414	13,377	32,325	40,124	34,731
Interest Expense	-2,242	-2,093	-1,683	-1,157	-924	-821
Interest & Investment Income	1,441	1,361	1,662	2,234	1,661	1,404
Earnings From Equity Investments	2,142	1,983	1,731	2,328	876	933
Currency Exchange Gain (Loss)	-1,150	-599	-796	48	40	442
Other Non Operating Income (Expenses)	-1,237	-4,898	-6,764	-4,669	-2,567	-2,089
EBT Excluding Unusual Items	10,952	10,168	7,527	31,109	39,210	34,600
Gain (Loss) on Sale of Investments	-859	-743	17,442	5,395	100	158
Gain (Loss) on Sale of Assets	-3,913	-2,543	-2,054	-3,086	-2,737	-2,455
Asset Writedown	-16,111	-16,111	-	-	-968	-
Legal Settlements	-	-	-	-	-	-2,997
Other Unusual Items	-	-7,853	-8,433	-18,829	-972	-253
Pretax Income	-13,105	-17,082	14,482	14,589	34,633	29,053
Income Tax Expense	1,578	-26	2,466	1,553	9,668	6,993
Earnings From Continuing Operations	-14,683	-17,056	12,016	13,036	24,965	22,060
Minority Interest in Earnings	5,134	4,756	-69	-268	1,047	725
Net Income	-9,549	-12,300	11,947	12,768	26,012	22,785
Net Income to Common	-9,549	-12,300	11,947	12,768	26,012	22,785
Net Income Growth	-	-	-6.43%	-50.91%	14.16%	0.36%
Shares Outstanding (Basic)	86	86	86	86	86	86
Shares Outstanding (Diluted)	86	86	86	86	86	86
Shares Change (YoY)	-0.01%	-0.02%	-0.04%	0.00%	-0.00%	-0.25%
EPS (Basic)	-110.81	-142.73	138.60	148.07	301.67	264.23
EPS (Diluted)	-110.81	-142.73	138.60	148.07	301.67	264.23
EPS Growth	-	-	-6.39%	-50.92%	14.17%	0.61%
Free Cash Flow	-	-40,132	-7,595	-29,855	5,275	3,782
Free Cash Flow Per Share	-	-465.69	-88.11	-346.23	61.17	43.86
Dividend Per Share	100.000	100.000	100.000	100.000	145.000	125.000
Dividend Growth	-	-	-	-31.03%	16.00%	-
Gross Margin	20.69%	21.14%	21.19%	25.11%	27.85%	28.27%
Operating Margin	3.01%	3.60%	3.44%	7.93%	10.43%	9.80%
Profit Margin	-2.39%	-3.07%	3.07%	3.13%	6.76%	6.43%
Free Cash Flow Margin	-	-10.03%	-1.95%	-7.32%	1.37%	1.07%
EBITDA	40,015	42,271	40,296	59,365	64,006	57,642
EBITDA Margin	10.03%	10.56%	10.35%	14.57%	16.63%	16.27%
D&A For EBITDA	28,017	27,857	26,919	27,040	23,882	22,911
EBIT	11,998	14,414	13,377	32,325	40,124	34,731
EBIT Margin	3.01%	3.60%	3.44%	7.93%	10.43%	9.80%
Effective Tax Rate	-	-	17.03%	10.64%	27.92%	24.07%

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.